Literature DB >> 19567246

Safety, reactogenicity and immunogenicity of Francisella tularensis live vaccine strain in humans.

H M El Sahly1, R L Atmar, S M Patel, J M Wells, T Cate, M Ho, K Guo, M F Pasetti, D E Lewis, M B Sztein, W A Keitel.   

Abstract

We evaluated the safety, reactogenicity and immunogenicity of escalating doses of a new Francisella tularensis Live Vaccine Strain (LVS) lot by scarification (SCAR) or subcutaneously (SQ) in humans. Subjects (N=10/group) received one dose of LVS via SCAR at 10(5),10(7) or 10(9)cfu/ml or SQ at 10(2), 10(3),10(4) or 10(5)cfu/ml; 14 subjects received placebo. All doses/routes were well tolerated. When compared to placebo, vaccination with 10(7) SCAR and 10(9) SCAR resulted in significantly higher serologic response frequencies, as measured by ELISA for IgG, IgM, IgA and microagglutination; whereas vaccination with 10(5) SCAR, 10(7) SCAR 10(9) SCAR and 10(5) SQ elicited a significantly higher interferon-gamma response frequency.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19567246      PMCID： PMC2726995          DOI： 10.1016/j.vaccine.2009.06.036

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  29 in total

1.  Tularemia vaccine study. I. Intracutaneous challenge.

Authors:  S SASLAW; H T EIGELSBACH; H E WILSON; J A PRIOR; S CARHART
Journal:  Arch Intern Med       Date:  1961-05

2.  Dominance of human innate immune responses in primary Francisella tularensis live vaccine strain vaccination.

Authors:  Claudette L Fuller; Katherine C Brittingham; Matthew J Hepburn; James W Martin; Patricia L Petitt; Phillip R Pittman; Sina Bavari
Journal:  J Allergy Clin Immunol       Date:  2006-03-31       Impact factor: 10.793

Review 3.  Vaccines against Francisella tularensis.

Authors:  J Wayne Conlan; Petra C F Oyston
Journal:  Ann N Y Acad Sci       Date:  2007-03-29       Impact factor: 5.691

4.  In vivo modulation of the murine immune response to Francisella tularensis LVS by administration of anticytokine antibodies.

Authors:  D A Leiby; A H Fortier; R M Crawford; R D Schreiber; C A Nacy
Journal:  Infect Immun       Date:  1992-01       Impact factor: 3.441

5.  Aerogenic immunization of man with live Tularemia vaccine.

Authors:  R B Hornick; H T Eigelsbach
Journal:  Bacteriol Rev       Date:  1966-09

6.  The requirement of tumour necrosis factor-alpha and interferon-gamma for the expression of protective immunity to secondary murine tularaemia depends on the size of the challenge inoculum.

Authors:  Anders Sjöstedt; Robert J North; J Wayne Conlan
Journal:  Microbiology (Reading)       Date:  1996-06       Impact factor: 2.777

Review 7.  The ecology of tularaemia.

Authors:  T Mörner
Journal:  Rev Sci Tech       Date:  1992-12       Impact factor: 1.181

Review 8.  Tularemia.

Authors:  Jill Ellis; Petra C F Oyston; Michael Green; Richard W Titball
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

9.  An improved Francisella tularensis live vaccine strain (LVS) is well tolerated and highly immunogenic when administered to rabbits in escalating doses using various immunization routes.

Authors:  Marcela F Pasetti; Lilian Cuberos; Thomas L Horn; Jeffry D Shearer; Stephen J Matthews; Robert V House; Marcelo B Sztein
Journal:  Vaccine       Date:  2008-01-29       Impact factor: 3.641

10.  Characterization of a novicida-like subspecies of Francisella tularensis isolated in Australia.

Authors:  Margaret J Whipp; Jennifer M Davis; Gary Lum; Jim de Boer; Yan Zhou; Scott W Bearden; Jeannine M Petersen; May C Chu; Geoff Hogg
Journal:  J Med Microbiol       Date:  2003-09       Impact factor: 2.472
View more
  28 in total

1.  Antibodies contribute to effective vaccination against respiratory infection by type A Francisella tularensis strains.

Authors:  Gopi Mara-Koosham; Julie A Hutt; C Rick Lyons; Terry H Wu
Journal:  Infect Immun       Date:  2011-01-31       Impact factor: 3.441

2.  Formulation and stabilization of Francisella tularensis live vaccine strain.

Authors:  Satoshi Ohtake; Russell A Martin; Atul Saxena; David Lechuga-Ballesteros; Araceli E Santiago; Eileen M Barry; Vu Truong-Le
Journal:  J Pharm Sci       Date:  2011-04-13       Impact factor: 3.534

3.  Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical Trial.

Authors:  Mark J Mulligan; Jack T Stapleton; Wendy A Keitel; Sharon E Frey; Wilbur H Chen; Nadine Rouphael; Srilatha Edupuganti; Allison Beck; Patricia L Winokur; Hana M El Sahly; Shital M Patel; Robert L Atmar; Irene Graham; Edwin Anderson; Samer S El-Kamary; Marcela F Pasetti; Marcelo B Sztein; Heather Hill; Johannes B Goll
Journal:  Vaccine       Date:  2017-07-24       Impact factor: 3.641

4.  Live attenuated mutants of Francisella tularensis protect rabbits against aerosol challenge with a virulent type A strain.

Authors:  Douglas S Reed; Le'kneitah P Smith; Kelly Stefano Cole; Araceli E Santiago; Barbara J Mann; Eileen M Barry
Journal:  Infect Immun       Date:  2014-03-10       Impact factor: 3.441

5.  Immunoproteomic analysis of the human antibody response to natural tularemia infection with Type A or Type B strains or LVS vaccination.

Authors:  Kelly M Fulton; Xigeng Zhao; Mireille D Petit; Sara L N Kilmury; Lawrence A Wolfraim; Robert V House; Anders Sjostedt; Susan M Twine
Journal:  Int J Med Microbiol       Date:  2011-08-27       Impact factor: 3.473

6.  IgM production by bone marrow plasmablasts contributes to long-term protection against intracellular bacterial infection.

Authors:  Rachael Racine; Maura McLaughlin; Derek D Jones; Susan T Wittmer; Katherine C MacNamara; David L Woodland; Gary M Winslow
Journal:  J Immunol       Date:  2010-12-08       Impact factor: 5.422

Review 7.  Technical transformation of biodefense vaccines.

Authors:  Shan Lu; Shixia Wang
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

8.  Immunoproteomics analysis of the murine antibody response to vaccination with an improved Francisella tularensis live vaccine strain (LVS).

Authors:  Susan M Twine; Mireille D Petit; Kelly M Fulton; Robert V House; J Wayne Conlan
Journal:  PLoS One       Date:  2010-04-02       Impact factor: 3.240

Review 9.  Live attenuated tularemia vaccines: recent developments and future goals.

Authors:  Mark E Marohn; Eileen M Barry
Journal:  Vaccine       Date:  2013-06-10       Impact factor: 3.641

Review 10.  Differential Immune Response Following Intranasal and Intradermal Infection with Francisella tularensis: Implications for Vaccine Development.

Authors:  McKayla J Nicol; David R Williamson; David E Place; Girish S Kirimanjeswara
Journal:  Microorganisms       Date:  2021-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.